Opinion

Video

Recent Data from INTERCEPT and COSMOS-CRC-01 in Colorectal Cancer: Part 2

Author(s):

John L. Marshall, MD,Benjamin Weinberg, MD

The panel continues its review of data presented on MRD testing in colorectal cancer from the INTERCEPT and COSMOS-CRC-01 studies.

Related Videos
Neil Iyengar, MD, and Chandler Park, MD, FACP
Stephen V. Liu, MD
Related Content
FDA
December 20th 2024

FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer

Mazyar Shadman, MD, MPH, associate professor, Clinical Research Division, medical director, Cellular Immunotherapy, Fred Hutchinson Cancer Center
December 19th 2024

Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH

Peter Martin, MD
December 2nd 2024

BTK Inhibitor–Based Combinations Represent the Future of MCL Management

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
October 24th 2024

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD

The Microbiome and Colon Cancer | Image Credit: © Anatomy Insider - stock.adobe.com
November 25th 2024

The Microbiome and Colon Cancer: Dietary Influence on Incidence, Morbidity, and Mortality

Sebastian Kaulitzki – stock.adobe.com
November 15th 2024

CHMP Recommends Approval of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC